SLAM
BBIO icon

Swiss Life Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Swiss Life Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$744K Buy
9,991
+1,085
+12% +$76K ﹤0.01% 794
2026
Q1 		$661K Buy
8,906
+2,151
+32% +$156K ﹤0.01% 774
2025
Q4 		$517K Buy
6,755
+89
+1% +$5.84K ﹤0.01% 785
2025
Q3 		$346K Buy
+6,666
New +$325K ﹤0.01% 844

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Swiss Life Asset Management's BBIO Position: Q2 2026 in Review

Swiss Life Asset Management increased its BridgeBio Pharma (BBIO) stake by 12% in Q2 2026, buying an estimated $76K and bringing the position to 9,991 shares worth $744K. The position accounts for ﹤0.01% of the portfolio, ranked #794.

Swiss Life Asset Management first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. 330 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Swiss Life Asset Management held 9,991 shares of BridgeBio Pharma worth $744K as of Q2 2026.
  • Swiss Life Asset Management bought 1,085 BridgeBio Pharma shares in Q2 2026, an estimated $76K.
  • BridgeBio Pharma made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #794 holding.
  • Swiss Life Asset Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • 330 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.